Genetics, drugs and environmental factors in Parkinson's disease: A Case-control Study

Arquivos de Neuro-Psiquiatria

Volumn 57, Issue 2 B, 1999, Pages 347-355

  Dos Santos Werneck, Antonio Luiz ^a,b   Alvarenga, Helcio ^a  

^a Servico Neurol do Hospilal C   (Brazil)

^b NONE   (Brazil)

Author keywords

Chemical agents; Drugs; Environmental factors; Genetics; Parkinson's disease

Indexed keywords

CHEMICAL AGENT; HERBICIDE; NEUROTOXIN; PESTICIDE; WELL WATER;

ARTICLE; CIGARETTE SMOKING; CONTROLLED STUDY; DRUG USE; ENVIRONMENTAL EXPOSURE; ENVIRONMENTAL FACTOR; HEREDITY; HUMAN; MAJOR CLINICAL STUDY; MULTIVARIATE ANALYSIS; PARKINSON DISEASE; RISK FACTOR;

EID: 0033024360     PISSN: 0004282X     EISSN: None     Source Type: Journal    
DOI: 10.1590/s0004-282x1999000300001     Document Type: Article

References (42)

1. Chan P, Tanner CM, Langston JW. Genetically determined differences in xenobiotic metabolism as a risk factor in Parkinson's disease. Fundam Appl Toxicol 1996;30(Suppl):89.
2. Chan P, Tanner CM, Langston JW. A new CYP2D6 mutation associated with Parkinson's disease in American Caucasians. Mov Disord 1995;10:689.
3. Myrianthopoulos NC, Kurland AA, Kurland LT. Hereditary predisposition in drug-induced Parkinsonism. Arch Neurol 1962;6:5-12.
4. Schwab RS, England AC. Parkinson's syndromes due to various specific causes. In Vinken PJ, Bruyn GH (eds). Handbook of clinical neurology. Armsterdam: North-Holland. 1975:248-266.
5. Calne DB, McGeer E, Eisen A, Spencer R. Alzheimer diosease. Parkinson's disease and motoneurone disease: abiotropic interaction between aging and environment? Lancet 1986;2:1067-1070.
6. Langston JW. Mechanisms underlying neuronal degeneration in Parkinson's disease: an experimental and theoretical treatise. Mov Disord 1989:4(Suppl 1):S15-S25.
7. Davis GC, Williams AC, Markey SP. et al. Chronic parkinsonism secondary to intravenous injection of meperidine-analog synthesis. Psychiat Res 1979;1:249-254.
8. Vingerhoets FJG, Snow BJ, Laugston JW, et al. Evolution of subclinical dopaminergic lesions in MPTP-exposed humans. Neurology 1993;43(Suppl2):A389.
9. Nicklas WJ, Vyas I, Heikilla RH. Inhibition of NADH-linked oxidation in brain mitochondria by 1-methyl-4-phenylpiridine, a metabolite of the neuroloxin 1 - methyl-4-phenyl-1.2.3.6-tetrahydropyridine. Life Sci 1985;36:2503-2508.
10. Schapira AHV, Cooper JM, Dexter E, Jenner P, Clack JB, Marsden CD. Mitochondrial complex I deficiency in Parkinson's disease. Lancet 1989;1:1269.
11. Burkhardt C, Kelly JP, Lim Y-H, Filley CM, Parker D, Jr. Neuroleptic medication inhibit complex I of the election transport chain. Ann Neurol 1993;33:512-517.
12. Veitch K, Hue L. Flunarizine and cinarizine inhibit complexes I and II: possible implications for Parkinsonism. Mol Pharmacol 1994;45:158-163.
13. Christenscn E, Moller JE, Faurbye A. Neuropathological investigation of 28 brains from patients with dyskynesia. Acta Psych Scand 1970;46:14-30.
14. Wilson JA, Primrose WR, Smith RG. Prognosis of drug-induced Parkinson's disease Lancet 1987;1:443-444.
15. Calne DB, Snow BJ, Lee C. Criteria for diagnosing Parkinson's disease. Ann Neurol 1992;32(Suppl):S132-S137.
16. Hughes AJ, Daniel SE, Kilford L, Lees AJ. Accuracy of clinical diagnosis of idiopathic Parkinson's disease; a clinico-pathologic study of 100 cases. J Neurol Neurosurg Psychiatry 1992;55:181-184.
17. Koller WC. How accurately can Parkinson's disease be diagnosed? Neurology 1992;42(Suppl 1):6-16.
18. Morens DM, Grandinetti A, Reed D, White LR, Ross GW. Cigarette smoking and protection from Parkinson's disease: false association or etiologic clue? Neurology 1995;45:1041-1045.
19. Reshef A, Rabey JM, Bar P, Schlosbeg: A, Korczyn AD. Smoking and drug-induced parkinsonism (Abstr). Neurology 1987;37(Suppl 1):121.
20. Duvoisin RC. The genetics of Parkinson's diascase. In Narabayashi H, Nagatsa T, Mizuno Y. (eds). Adv Neurol. 1991:306-315.
21. Calne S, Shoenberg B, Martin W, et al. Familial Parkinson's disease: possible role of environmental factors. Can J Neurol Sci 1987;14:303-305.
22. Martin WE, Young WI, Anderson VL. Parkinson's disease: a genetic study. Brain 1973;96:495-506.
23. Chase TN, Schnur JA, Gordon EK. Cerebrospinal fluid monoamine catabolites in drug-induced extrapyramidal disorders. Neuropharmacology 1970;9:265-275.
24. Barbeau A, Cloutier T, Roy M, Plasse L, Poirier J. Ecogenetics of Parkinson's disease: 4-hydroxilation of debrisoquine. Lancet 1985;2:1213-1216.
25. Ferraz HB, Bertolucci HF, Pereira JS, Lima AHV. Andrade LAF. Chronic exposure to the fungicide maneb may produce symptoms and signs of manganese intoxication. Neurology 1988;38:550-553.
26. Ballard PA, Tetrud JW, Langston JW. Permanent human parkinsonism due to 1-methyl-4-phenyl-1,2,3,6-tertahydiopiridine (MPTP): seven cases. Neurology 1985;35:949-956.
27. Semchuck KM, Love LI, Lee RG. Parkinson's disease: a test of the multifactorial etiologic hypothesis Neurology 1993;43:1173-1180.
28. Tanner CM, Chen B, Wang W, et al. Environmental factors and Parkinson's disease: a case-control in China. Neurology 1989;39:660-664.
29. Ngim CH, Devathanam G. Epidemiologic study on the association between body burden mercury levels and idiopathic Parkinson's disease. Neuroepidemiology 1989;8:128-141.
30. Gorell JM, Johnson CC, Rybicki BA, et al. Occupational exposures to metals as risk factors for Parkinson's disease. Neurology 1997;48:650-658.
31. Tetud JW, Langston JW, Irwin I, Snow B. Parkinsonism caused by petroleum waste ingestion. Neurology 1994;44:1051-1054.
32. Rajput AH, Rozdilsky B, Hornykiewcz. O, Shannack K, Lee T, Seeman P. Reversible drug-induced parkinsonism. Arch Neurol 1982;39:644-646.
33. Bamrah JS, Soni SD. Drug-induced Parkinson's disease Lancet 1987;1:1031-1032.
34. Melo Souza SE. Flunarizina, parkinsonismo e depressāo (Abstr). Goīania: XI Congresso Brasileiro de Neurologia. 1984,p39.
35. Chouza C, Caamaño JZ. De Medina O, Scaramelli A, Aljinati R. Funarizine-induced extrapyramidal syndrome (Abstr). New York:VIII International Symposium on Parkinson's Disease, 1985:96.
36. Subramanyan B, Rollema H, Woolf T, Castagnoli N Jr. Identification of a potential neurotoxic pyridinium metabolic of haloperidol in rats. Bioch Bioph Res Comm 1990;166:238-244.
37. Haas HH, Chir B, Nasirian F, et al. Low platelet mitochondrial complex I and complex II/III activity in early untreated Parkinson's disease. Ann Neurol 1995;37:714-722.
38. De Vries D, Beart PM. Competitive inhibition of (3 H)spirone binding to D-2 dopamine receptors in striatal homogenates by organic calcium channel antagonists and poyvalent cations. Eur J Pharmacol 1984;106:133-139.
39. Figiel GS, Krishnan RR, Doraiswamy M, Nemeroff CB. Caudate hyperintensities in elderly depressed patients with neuroleptic-induced parkinsonism. J Geriatr Psychiatry Neurol 1991;4:86-89.
40. Bocola V, Fabbrini G, Sollecito A, Paladini C, Martucci N. Neuroleptic induced parkinsonism: MRI findings in relation to clinical course after withdrawal of neuroleplic drugs. J Neurol Neurosurg Psichiatry 1996;60:213-216.
41. Ben-Slachar D, Youdim MBH. Neuroleptic induced dopamine receptor supersensivity and tardive dyskinesia may involve altered brain iron metabolism. Br J Pharmacol 1987;90:95.
42. 11 C] RTI-32 PET studies of the dopamine transporter in early dopa-naive Parkinson's disease: implications for the symptomatic threshold. Neurology 1997;48;1578-1583.